During ASCO’s 2023 Annual Meeting investigators shared findings from several neoadjuvant studies, including KEYNOTE-671 and Neotorch, which showed improved EFS with pembrolizumab and toripalimab, respectively. Read more
Is “resectability” based on radical resection criteria still valid in the era of neoadjuvant immunochemotherapy? ILCN’s editors say the term needs to be revisited and probably redefined based on a tumor’s status before treatment and after neoadjuvant treatment. Read more
Despite access to free treatment within the National Health Service, patients in the most deprived areas were 55% less likely to receive targeted therapies, biologic treatments, and immunotherapy compared to residents in the least deprived areas. Read more
Carolyn Dresler, MD, MPA, and Chris Bostic, JD, say plans to reduce the prevalence and impact of lung cancer must address smoking if they are to succeed. Read more
Researchers examine emerging data demonstrating that functionally distinct arrhythmia classes are associated with radiotherapy dose to discrete cardiac substructures. These observations may help guide potential mitigation efforts for lung cancer patients undergoing radiotherapy. Read more
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC. Read more
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question. Read more
Advocacy group says its annual research events are key to its mission: Making EGFR-mutated lung cancer a manageable chronic disease. Read more
Health Canada gives greenlight to cemiplimab-chemo combo for first-line treatment of advanced NSCLC. Early registration for WCLC 23 ends June 9. Read more
During a recent interview with ILCN, Prof. Swanton reviewed the possible mechanisms at play when particulate matter triggers cancer growth and discussed new data that sheds additional light on the process. Read more